Swiss food conglomerate Nestle is reportedly expanding its skincare portfolio after acquiring various injectable treatment patents in a $1.4 billion deal.
Reports say Nestle acquired the rights for various wrinkle treatments from Valeant Pharmaceuticals.
While the deal allows Nestle to own the rights to treatments acquired when it fully took over its joint venture with Galderma, the transaction poses benefits for Valeant, as well. According to reports, the sale unloads a possible antitrust hurdle for Valeant, which is looking to acquire US Botox maker Allergan.
Some analysts, however, doubt that the acquisition will be as beneficial to Nestle as intended. The company has been looking for years to expand from a confectionary company into a global healthcare and nutrition brand; some experts, reports say, doubt that winkle treatment fits under that market.
Full content: International Business Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian School Boards Sue Social Media Giants for $4 Billion
Mar 28, 2024 by
CPI
Alaska Airlines and Hawaiian Airlines Enter Timing Agreement with DOJ
Mar 28, 2024 by
CPI
Sam Bankman-Fried Gets 25-Year Sentence for $8B Crypto Fraud
Mar 28, 2024 by
CPI
Walmart Withdraws and Refiles Antitrust Review Application for Vizio Acquisition
Mar 28, 2024 by
CPI
Apple Prevails in Dismissal of Crypto-Payment Antitrust Lawsuit
Mar 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI